What Abiogen Pharma does

Abiogen Pharma is an Italian pharmaceutical company founded in 1997 and headquartered in Pisa, with roots spanning five generations of the Di Martino family. The company is owned via MDM Holding S.p.A. and operates across six therapeutic areas: bone metabolism and musculoskeletal, hypovitaminosis D, pain and viscosupplementation, dermatology, respiratory, and diabetology. Its flagship technological differentiator is an internally developed portfolio of bisphosphonate molecules (Etidronate, Clodronate, Alendronate, Neridronate), with Neridronate holding first-in-class Italian approvals for rare diseases osteogenesis imperfecta and CRPS, plus FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations for U.S. development.

The commercial portfolio comprises branded pharmaceutical drugs (Dibase vitamin D, Nerixia/neridronate, Clasteon, Binosto effervescent alendronate, Acetamol analgesics, Januvia/Janumet via MSD licence), medical devices (Cingal, Jonexa Up cross-linked hyaluronic acid for viscosupplementation), food supplements (Calciobase, D3Base Junior), and Sarcobase — a patented L-leucine, Omega 3, and L. paracasei composition for muscle trophism. Manufacturing is fully vertically integrated at a 120,000 m2 Pisa site with GMP certification since 2005 (EU-GMP Annex 13), spanning oral solids (350-400 tons/yr), injectables (35M ampoules/yr), semi-solids, liquids, liquid-filled capsules, and sticks; the site also runs a CMO/CDMO business for third-party clients.

The business model is multi-stream: (1) branded pharma and supplement sales in Italy via a 150-strong Scientific Representative field force under D. Leg.vo 219/06 compliance; (2) international distribution through a licensing-out network of 20+ partners across 40+ countries; (3) direct subsidiary sales in Germany (Altamedics, acquired December 2022) and Switzerland (EffRx, 97.09% acquired May 2023); and (4) CMO/CDMO services. Reported 2024 revenue was EUR 168 million (Italian domestic EUR 141.7 million) with 460 employees as of 31 December 2024.

Name

Abiogen Pharma

Legal name

Abiogen Pharma S.p.A.

Website

https://abiogen.it

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

251–500 employees

Short description

Abiogen Pharma is an Italian pharmaceutical company founded in 1997 that develops, manufactures, and commercializes branded drugs, bisphosphonates, medical devices, and supplements across bone, pain, dermatology, respiratory, and diabetology therapeutic areas, serving Italian NHS and specialty physicians directly and 40+ countries via licensing partners and European subsidiaries.

Ownership category

akta.pro rank

Headquarters

HQ city

Pisa

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of branded pharmaceutical drugs, medical devices, food supplements, and foods for special medical purposes across six therapeutic areas (bone metabolism, hypovitaminosis D, pain/viscosupplementation, respiratory, dermatology, diabetology) through direct sales force in Italy and distributor/partner networks internationally. Revenue reported at EUR 168 million in 2024, with Italian domestic turnover of EUR 141,706,708 in 2024.
2. Contract Manufacturing (CMO/CDMO): Contract development and manufacturing services for external pharmaceutical clients offering formulation development, analytical testing, scale-up, and commercial production. Services span from early clinical phases through commercial scale across multiple dosage forms.
3. Licensing Out: Licensing out proprietary products and molecules to international pharmaceutical partners for commercialization in their respective territories. More than 20 partners across over 40 countries. Products include Acetamol, Codamol, Clasteon, Dibase, Gliconorm, Sursum, and food supplements.
4. Licensing In: Licensing in products from international pharmaceutical partners for commercialization in Italy. Partners include Anika Therapeutics (hyaluronic acid/Cingal), Om Pharma (Broncho Munal), Mabxience, ImasMed (Jonexa Up), Hisamitsu Pharmaceutical (Ketoprofene/Keplat), MSD (Januvia/Janumet), Organon Italia (Alendronato/Alendros), Galenica AB, Synthon B.V., and Bened Biomedical LTD.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Abiogen Pharma is an Italian pharmaceutical company that develops, manufactures, and commercializes prescription drugs (notably bisphosphonates such as neridronate, clodronate, alendronate, and etidronate), vitamin D products, analgesics, and treatments for diabetes, dermatology, and respiratory conditions. In addition to its proprietary drug portfolio, the company sells medical devices for viscosupplementation, food supplements and foods for special medical purposes, and offers contract manufacturing and development (CMO/CDMO) services to third-party pharmaceutical clients across multiple dosage forms.

Product overview

Abiogen Pharma is an Italian pharmaceutical company founded in 1997, operating in bone metabolism, musculoskeletal, pain management, and related therapeutic areas. The company offers a diversified portfolio comprising: (1) Pharmaceutical drugs including bisphosphonates (NERIXIA/neridronate, CLASTEON/clodronate, BINOSTO/alendronate, ALENDROS), vitamin D products (DIBASE, DIBASELAB), analgesics (ACETAMOL/paracetamol, CODAMOL), and treatments for diabetes, dermatology, and respiratory conditions; (2) Medical devices including viscosupplementation products (CINGAL, JONEXA UP) with cross-linked hyaluronic acid; (3) Food supplements including calcium citrate (CALCIOBASE) and vitamin D3 (D3BASE JUNIOR) for bone health; (4) Foods for special medical purposes (SARCOBASE) for muscle support; and (5) Contract manufacturing services (CMO/CDMO). The company operates through domestic Italian sales organization, international licensing partnerships covering 40+ countries, and direct presence via subsidiaries (EffRx Pharmaceuticals, Altamedics).

Differentiator

Problem solved

Functional benefit

Products and services

• ACETAMOL Paracetamol-based analgesic for pain and fever relief, available in multiple formulations including tablets, suppositories, syrup, and effervescent tablets for adults and children.
• ALENDROS Alendronate tablet for the treatment of osteoporosis, belonging to the bisphosphonate class; licensed in from Organon Italia for the Italian market.
• BINOSTO Effervescent sodium alendronate tablet for treatment of postmenopausal osteoporosis; flagship product acquired from EffRx Pharmaceuticals.
• DIBASE Cholecalciferol (vitamin D3) product for prevention and treatment of vitamin D deficiency, available in multiple dosages from 2,000 to 300,000 IU.
• NERIXIA Sodium neridronate injection for metabolic osteopathies; the first drug to obtain Italian regulatory approval for rare diseases such as osteogenesis imperfecta and algodystrophy (CRPS).
• CINGAL Cross-linked hyaluronic acid with ancillary triamcinolone hexacetonide medical device supplied in 5ml glass syringe for viscosupplementation in osteoarthritis; licensed in from Anika Therapeutics.
• JONEXA UP Cross-linked hyaluronic acid medical device for intra-articular injection in osteoarthritis treatment; licensed in from ImasMed.
• CALCIOBASE Calcium citrate supplement in stick format for bone health, gluten/lactose/sugar free.
• D3BASE JUNIOR Vitamin D3 supplement in gumdrop form for children above 4 years, available in Orange and Wild Berries flavors, 600 IU per serving.
• SARCOBASE Food for special medical purposes with L-leucine, Omega 3 and Lactobacillus paracasei patented composition for muscle trophism support.
• Contract Manufacturing (CMO/CDMO) Contract development and manufacturing services for third-party pharmaceutical clients offering formulation development, analytical testing, scale-up, and commercial production across orals, injectables, semisolids, oral liquids, liquid-filled capsules, and sticks.

Quantifiable outcome

• Revenue of EUR 168 million in 2024
• +3 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Ambros TherapeuticscoreStrategic or Co-development PartnerAbiogen Pharma licensed neridronate to Ambros Therapeutics for development and commercialization outside Italy. Ambros Therapeutics launched in December 2025 with $125 million Series A funding to conduct Phase 3 CRPS-RISE trial of neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1) in the United States. Neridronate has already received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. First patient dosed June 2026.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights9 records

Customer concentration

• Facebookfacebook.com/271856682833296
• LinkedInlinkedin.com/company/abiogen-pharma-s.p.a.

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abiogen Pharma